they deliver bioactive compounds that support blood sugar regulation, gut health and GLP-1 signaling
Weeks 9-12 advance to 8mg weekly
Only within-trial comparisons should be treated as causal
These progressions matter because progressive overload, the systematic increase of training stress over time, is what drives adaptation
But with Mounjaro, that number could be closer to 40 poundsor even more
1-8 Recent European Society of Cardiology guidelines for the management of cardiovascular disease (CVD) in patients with diabetes state that GLP-1 RAs (lixisenatide, liraglutide, semaglutide, exenatide extended release [ER], dulaglutide, efpeglenatide) should be considered for glucose-lowering treatment in patients with T2D at risk of or with heart failure (HF